NTRA vs CYBR Comparison

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

CyberArk is a cybersecurity vendor focused on the identity market. The company's core privileged access management offering is a market leader in that subsegment, with more than half of the Fortune 500 as CyberArk customers. The identity security vendor was founded in 1999 and has around 9,000 customers across various industries. While CyberArk historically sold its security solutions primarily via on-premises licenses, over the past few years it has transitioned to a subscription recurring-revenue model.